New Novartis Data Reveals Cosentyx® is Superior to Stelara® in Psoriasis Patients

Novartis presented new data from the head-to-head CLEAR study demonstrating that Cosentyx^® (secukinumab) remains superior to Stelara^® (ustekinumab) in achieving sustained skin clearance (PASI 90 response) at 52 weeks for adults living with moderate-to-severe psoriasis.
According to the news:

Cosentyx^® is the first fully human interleukin-17A inhibitor approved for adults to treat moderate-to-severe plaque psoriasis, and was recently approved for the treatment of psoriatic arthritis and ankylosing spondylitis in the EU and US.

Dr. Ron Vender, MD FRCPC, Director of Dermatrials Research Inc. and Venderm Innovation in Psoriasis and investigator for the CLEAR study, said:

This is an important milestone in the treatment of psoriasis, a skin disease with significant physical and emotional impact on a patient’s life. I am encouraged by the data from the CLEAR study as it validates Cosentyx^® as an effective treatment option for Canadians managing moderate-to-severe psoriasis whose treatment goals include long-lasting skin clearance.

Click here to view the full press release.